E. E. Holdener

809 total citations
16 papers, 611 citations indexed

About

E. E. Holdener is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, E. E. Holdener has authored 16 papers receiving a total of 611 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Epidemiology. Recurrent topics in E. E. Holdener's work include Retinoids in leukemia and cellular processes (3 papers), Renal cell carcinoma treatment (2 papers) and Bladder and Urothelial Cancer Treatments (2 papers). E. E. Holdener is often cited by papers focused on Retinoids in leukemia and cellular processes (3 papers), Renal cell carcinoma treatment (2 papers) and Bladder and Urothelial Cancer Treatments (2 papers). E. E. Holdener collaborates with scholars based in Switzerland, United States and Germany. E. E. Holdener's co-authors include Wendy B. Bollag, Genevieve Decoster, Gerburg M. Stein, Sophie D. Fosså, George Schneider, Ulrich Otto, Giovanni Martinelli, F Oberling, H Bauer and F. Calabresi and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and British Journal of Haematology.

In The Last Decade

E. E. Holdener

16 papers receiving 578 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. E. Holdener Switzerland	10	255	187	128	117	92	16	611
Ram Chillar United States	12	171 0.7×	174 0.9×	58 0.5×	70 0.6×	50 0.5×	17	589
Jan M. Werre Netherlands	9	341 1.3×	101 0.5×	330 2.6×	85 0.7×	135 1.5×	10	1.0k
Lisa Barroilhet United States	21	356 1.4×	216 1.2×	66 0.5×	202 1.7×	85 0.9×	62	1.1k
Daniel G. Miller United States	11	129 0.5×	220 1.2×	74 0.6×	65 0.6×	72 0.8×	23	661
W.R. Bezwoda South Africa	16	204 0.8×	367 2.0×	95 0.7×	196 1.7×	71 0.8×	41	891
César Gómez-Raposo Spain	13	132 0.5×	179 1.0×	99 0.8×	73 0.6×	34 0.4×	41	555
Yeşim Eralp Türkiye	21	186 0.7×	555 3.0×	279 2.2×	344 2.9×	103 1.1×	94	1.3k
James E. Ward United States	12	340 1.3×	360 1.9×	100 0.8×	48 0.4×	63 0.7×	16	730
G. Salerno Italy	13	78 0.3×	197 1.1×	53 0.4×	41 0.4×	47 0.5×	20	552
Eleanor V. Willett United Kingdom	14	281 1.1×	331 1.8×	59 0.5×	90 0.8×	103 1.1×	22	1.0k

Countries citing papers authored by E. E. Holdener

Since Specialization

Citations

This map shows the geographic impact of E. E. Holdener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. E. Holdener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. E. Holdener more than expected).

Fields of papers citing papers by E. E. Holdener

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. E. Holdener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. E. Holdener. The network helps show where E. E. Holdener may publish in the future.

Co-authorship network of co-authors of E. E. Holdener

This figure shows the co-authorship network connecting the top 25 collaborators of E. E. Holdener. A scholar is included among the top collaborators of E. E. Holdener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. E. Holdener. E. E. Holdener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Kavanagh, J. J., M. Paredes-Espinoza, Patricia Paredes-Casillas, et al.. (1996). The combination of 13-cis-retinoic acid and interferon alpha2a with radiation therapy in squamous cell carcinoma of the cervix. International Journal of Gynecological Cancer. 6(6). 439–444. 9 indexed citations

Fosså, Sophie D., Monica Jones, Peter Johnson, et al.. (1995). Interferon‐alpha and survival in renal cell cancer. British Journal of Urology. 76(3). 286–290. 33 indexed citations

Lippman, Scott M., Bonnie S. Glisson, John J. Kavanagh, et al.. (1993). Retinoic acid and interferon combination studies in human cancer. European Journal of Cancer. 29. S9–S13. 40 indexed citations

Tura, S, Domenico Russo, Elisa Zuffa, et al.. (1992). A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica. 77(3). 204–214. 15 indexed citations

Fosså, Sophie D., Giovanni Martinelli, Ulrich Otto, et al.. (1992). Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study. Annals of Oncology. 3(4). 301–305. 76 indexed citations

Bollag, Wendy B. & E. E. Holdener. (1992). Retinoids in cancer prevention and therapy. Annals of Oncology. 3(7). 513–526. 185 indexed citations

Kruit, Wim H.J., S.H. Goey, J. R. T. Monson, et al.. (1991). Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma. British Journal of Haematology. 79(s1). 84–86. 23 indexed citations

Boccoli, G, R Masciulli, G. Salvo, et al.. (1990). Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. European Journal of Cancer and Clinical Oncology. 26(11-12). 1152–1156. 47 indexed citations

Decoster, Genevieve, Gerburg M. Stein, & E. E. Holdener. (1990). Responses and toxic deaths in Phase I clinical trials. Annals of Oncology. 1(3). 175–181. 127 indexed citations

10.

Obrist, R., et al.. (1990). Improved Tolerance of Interferon alpha-2a by Continuous Subcutaneous Infusion. Oncology Research and Treatment. 13(2). 117–122. 4 indexed citations

11.

Alberto, P., Johannes Winkelmann, Arnaud Bruyère, et al.. (1989). Phase I study of oral doxifluridine using two schedules. European Journal of Cancer and Clinical Oncology. 25(5). 905–908. 13 indexed citations

12.

Holdener, E. E., Peter Spieler, W Angehrn, et al.. (1986). [Malignant pericardial effusion--a sign of unfavorable prognosis?].. PubMed. 116(12). 366–70. 3 indexed citations

13.

Tenschert, W., et al.. (1985). Secondary hypertension and neurofibromatosis: Bilateral renal artery stenosis and coarctation of the abdominal aorta. Journal of Molecular Medicine. 63(13). 593–596. 9 indexed citations

14.

Holdener, E. E., R Nissen-Meyer, Gianni Bonadonna, et al.. (1984). Second Malignant Neoplasms in Operable Carcinoma of the Breast. Recent results in cancer research. 96. 188–196. 23 indexed citations

15.

Hansen, Mads, Jan B. Vermorken, E. E. Holdener, et al.. (1984). Phase II trial of diaziquone in advanced renal adenocarcinoma.. PubMed. 68(7-8). 1055–6. 2 indexed citations

16.

Bramwell, Vivien, E. E. Holdener, P Siegenthaler, et al.. (1984). Phase II study of Amsacrine in refractory lymphomas. A report of the EORTC early clinical trials group. European Journal of Cancer and Clinical Oncology. 20(6). 753–759. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact